The willingness of patients to accept an additional mortality risk in order to improve renal graft survival

Kidney International

Volumn 66, Issue 1, 2004, Pages 375-382

  Girardi, Vincenzo ^a   Schaedeli, Franziska ^a   Marti, Hans Peter ^a   Frey, Felix J ^a   Uehlinger, Dominik E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Decision analysis; Immunosuppression; Renal transplantation; Standard gamble; Time trade off

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DIALYSIS; FEMALE; GRAFT SURVIVAL; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERVIEW; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; PATIENT ATTITUDE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 3042848824     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00740.x     Document Type: Article

References (43)

1. GASTON RS: Maintenance immunosuppression in the renal transplant recipient: An overview. Am J Kidney Dis 38:S25-S35, 2001
2. CHARPENTIER B, HIESSE C, DURRBACH A, et al: Overview of clinical trials with new agents. Transplant Proc 33:2201-2203, 2001
3. PETRIE JJ, RIGBY RJ, HAWLEY CM, et al: Effect of OKT3 in steroid-resistant renal transplant rejection. Transplantation 59:347-352, 1995
4. WALZ MK, ALBRECHT KH, NIEBEL W, EIGLER FW: De novo malignant tumors during drug immunosuppression. The findings following 1245 cadaveric kidney transplants in 1080 patients. Dtsch Med Wschr 117:927-934, 1992
5. NICHOLSON V, JOHNSON PC: Infectious complications in solid organ transplant recipients. Surg Clin North Am 74:1223-1245, 1994
6. CARMELLINI M, ROMAGNOLI J, PIETRABISSA A, et al: Evaluation of infections in renal transplant recipients treated with cyclosporine. Transplant Proc 26:2658-2659, 1994
7. GARCIA VD, KEITEL E, ALMEIDA P, et al: Morbidity after renal transplantation: Role of bacterial infection. Transplant Proc 27:1825-1826, 1995
8. BILGIN N, KARAKAYALI H, MORAY G, et al: Incidence of cytomegalovirus infection in kidney recipients. Transplant Proc 4:2314-2315, 1996
9. LEIGH IM, GLOVER MT: Skin cancer and warts in immunosuppressed renal transplant recipients. Cancer Research 139:69-86, 1995
10. PENN I: Tumors of the immunocompromised patient. Ann Rev Med 88:63-73, 1988
11. REIS MA, COSTA RS, FERRAZ AS: Causes of death in renal transplant recipients: A study of 102 autopsies from 1968 to 1991. J R Soc Med 88:24-27, 1995
12. SGRO C: Side effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: Bibliographic review. Toxicology 105:23-29, 1995
13. MELOSKY B, KARIM M, CHUI A, et al: Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression. J Am Soc Nephrol 2:290-294, 1992
14. HIRSCH HH, KNOWLES W, DICKENMANN M, et al: Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347:488-496, 2002
15. DE MAAR EF, VERSCHUUREN EA, HOMAN VD, HEIDE JJ, et al: Effects of changing immunosuppressive regimen on the incidence, duration, and viral load of cytomegalovirus infection in renal transplantation: A single center report. Transpl Infect Dis 4:17-24, 2002
16. DANTAL J, HOURMANT M, CANTAROVICH D, et al: Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporine regimens. Lancet 351:623-628, 1998
17. SOLOMON H, GONWA TA, MOR E, et al: OKT3 rescue for steroid-resistant rejection in adult liver transplantation. Transplantation 55:87-91, 1993
18. DEEB GM, BOLLING SF, STEIMLE CN, et al: A randomized prospective comparison of MALG with OKT3 for rescue therapy of acute myocardial rejection. Transplantation 51:180-183, 1991
19. DEIERHOI MH, BARBER WH, CURTIS JJ, et al: A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection. Am J Kidney Dis 11:86-89, 1988
20. COSIMI AB, CHO SI, DELMONICO FL, et al: A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 43:91-95, 1987
21. MCNUTT RA: Measuring patient preferences for health outcomes: A decision analytic approach. Patient Educ Couns 13:271-279, 1989
22. TORRANCE GW, THOMAS WH, SACKETT DL: A utility maximization model for evaluation of health care programs. Health Service Res 7:118-133, 1972
23. TORRANCE GW: Measurement of health state utilities for economic appraisal. A review. J Health Econ 5:1-30, 1986
24. VON NEUMANN J, MORGENSTERN O: Theory of Games and Exonomic Behaviour, New York, John Wiley, 1953
25. WEINSTEIN M, FINEBERG H: Utility analysis: Clinical decision involving many possible outcomes (chapter 7), in Clinical Decision Analysis, Philadelphia, Saunders, 1980, pp 184-227
26. HOLLOWAY C: Decision Making Under Uncertainty: Models and Choices, Englewood Cliffs (NJ), Prentice-Hall, 1979
27. FROBERG DG, KANE RL: Methodology for measuring health-state preferences: II. Scaling methods. J Clin Epidemiol 42:459-471, 1989
28. CEBUL R, BECK L: Teaching Clinical Decision Making, New York, Praeger, 1985
29. READ JL, QUINN RJ, BERWICK DM, et al: Preferences for health outcomes. Comparison of assessment methods. Med Decis Making 4:315-329, 1984
30. RAIFFA H: Decision Analysis: Introductory Lectures on Choice of Uncertainty, Menlo Park (CA), Addison-Wesley, 1968
31. TORRANCE G: Social preferences for health states: An empirical evaluation of three measurement techniques. Socio Econ Plan Sci 10:128-136, 1976
32. DRUMMOND MF: Discussion: Torrance's "Utility approach to measuring health-related quality of life." J Chron Dis 40:601-603, 1987
33. UNITED STATES RENAL DATA SYSTEM: Excerpts from United States Renal Data System (USRDS) 1995 Annual Data Report. Am J Kidney Dis 26:82, 1995
34. BLAND JM, ALTMAN DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310, 1986
35. CHURCHILL DN, TORRANCE GW, TAYLOR DW, et al: Measurement of quality of life in end-stage renal disease: The time trade-off approach. Clin Invest Med 10:14-20, 1987
36. DE WIT GA, MERKUS MP, KREDIET RT, DE CHARRO FT: Health profiles and health preferences of dialysis patients. Nephrol Dial Transplant 17:86-92, 2002
37. TVERSKY A, KAHNEMAN D: The framing of decisions and the psychology of choice. Science 211:453-458, 1981
38. MCNEIL BJ, PAUKER SG, SOX HCJ, TVERSKY A: On the elicitation of preferences for alternative therapies. N Engl J Med 306:1259-1262, 1982
39. TORRANCE GW: Utility approach to measuring health-related quality of life. J Chron Dis 40:593-600, 1987
40. GROOME PA, HUTCHINSON TA, TOUSIGNANT P, HANLEY JA: The repeatability of three methods for measuring prospective patients' values in the context of treatment choice for end-stage renal disease. J Clin Epidemiol 52:849-860, 1999
41. BOSCH JL, HAMMITT JK, WEINSTEIN MC, HUNINK MG: Estimating general-population utilities using one binary- gamble question per respondent. Med Decis Making 18:381-390, 1998
42. VAN WIJCK EE, BOSCH JL, HUNINK MG: Time-tradeoff values and standard-gamble utilities assessed during telephone interviews versus face-to-face interviews. Med Decis Making 18:400-405, 1998
43. LENERT LA, MORSS S, GOLDSTEIN MK, et al: Measurement of the validity of utility elicitations performed by computerized interview. Med Care 35:915-920, 1997